Coronary Bypass with PTCA without MCC DRG Reimbursement

DRG 232 includes coronary artery bypass surgery performed with percutaneous transluminal coronary angioplasty in the absence of a Major Complication or Comorbidity, encompassing combined surgical and percutaneous coronary revascularization. This Diagnosis-Related Group determines inpatient reimbursement under Medicare by grouping cases with similar clinical resource needs and guiding prospective payment rates.

DRG 232 Overview

DRG 232 covers inpatient cases involving coronary artery bypass grafting combined with percutaneous transluminal coronary angioplasty, without a Major Complication or Comorbidity. This Diagnosis-Related Group applies when both surgical bypass and percutaneous intervention occur during the same hospitalization and no Major Complication or Comorbidity is coded. It matters for Medicare payment because the combined procedures influence resource use and payment relative to isolated revascularization cases.

Acute procedural optimization studies: randomized or prospective cohort studies comparing intraoperative strategies during combined coronary artery bypass grafting (CABG) with percutaneous transluminal coronary angioplasty (PTCA) or staged PCI, such as variations in timing (simultaneous versus staged procedures), graft selection and conduit handling, or intraoperative hemodynamic/anticoagulation protocols. These trials enroll adult patients undergoing hybrid revascularization for multivessel coronary artery disease without major complications, aiming to define approaches that reduce perioperative myocardial injury, bleeding, or operative time. Results directly inform surgical and catheterization suite workflows, resource utilization, and short-term complication rates that drive inpatient costs and DRG assignment for providers and payers.
Comparative effectiveness and device/technique evaluation: pragmatic studies comparing different revascularization strategies (eg, hybrid CABG+PTCA versus isolated CABG or multivessel PCI) or specific device/technique choices (type of stent or graft conduit, use of off-pump versus on-pump CABG) in patients who are candidates for combined procedures. These studies typically enroll patients with complex coronary anatomy or comorbidities stratified by surgical risk, seeking real-world outcomes such as in-hospital morbidity, length of stay, readmission, and need for repeat revascularization. Findings help clinicians select approaches that balance clinical benefit and cost-effectiveness, which affects case mix, reimbursement profiles, and payer coverage decisions within this DRG.
Post-discharge outcomes and care transition research: observational cohorts and interventional trials focused on early post-discharge outcomes for patients after CABG with PTCA, including studies of coordinated discharge planning, cardiac rehabilitation initiation, medication adherence programs, and remote monitoring to prevent early readmission and detect graft or stent failure. These studies enroll patients discharged after an uncomplicated combined revascularization episode to measure 30- and 90-day readmission rates, functional recovery, and secondary prevention adherence. Results are highly relevant to hospitals and payers because reductions in readmissions and improved post-acute management can lower total episode costs, inform bundled payment strategies, and improve quality metrics tied to this DRG.

Acute procedural optimization studies: randomized or prospective cohort studies comparing intraoperative strategies during combined coronary artery bypass grafting (CABG) with percutaneous transluminal coronary angioplasty (PTCA) or staged PCI, such as variations in timing (simultaneous versus staged procedures), graft selection and conduit handling, or intraoperative hemodynamic/anticoagulation protocols. These trials enroll adult patients undergoing hybrid revascularization for multivessel coronary artery disease without major complications, aiming to define approaches that reduce perioperative myocardial injury, bleeding, or operative time. Results directly inform surgical and catheterization suite workflows, resource utilization, and short-term complication rates that drive inpatient costs and DRG assignment for providers and payers.
Comparative effectiveness and device/technique evaluation: pragmatic studies comparing different revascularization strategies (eg, hybrid CABG+PTCA versus isolated CABG or multivessel PCI) or specific device/technique choices (type of stent or graft conduit, use of off-pump versus on-pump CABG) in patients who are candidates for combined procedures. These studies typically enroll patients with complex coronary anatomy or comorbidities stratified by surgical risk, seeking real-world outcomes such as in-hospital morbidity, length of stay, readmission, and need for repeat revascularization. Findings help clinicians select approaches that balance clinical benefit and cost-effectiveness, which affects case mix, reimbursement profiles, and payer coverage decisions within this DRG.
Post-discharge outcomes and care transition research: observational cohorts and interventional trials focused on early post-discharge outcomes for patients after CABG with PTCA, including studies of coordinated discharge planning, cardiac rehabilitation initiation, medication adherence programs, and remote monitoring to prevent early readmission and detect graft or stent failure. These studies enroll patients discharged after an uncomplicated combined revascularization episode to measure 30- and 90-day readmission rates, functional recovery, and secondary prevention adherence. Results are highly relevant to hospitals and payers because reductions in readmissions and improved post-acute management can lower total episode costs, inform bundled payment strategies, and improve quality metrics tied to this DRG.

OpenPayer

Summary & Overview

Coronary Bypass with PTCA without MCC: Inpatient Reimbursement Overview

DRG 232 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes